載入中
NYSEHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$9.32
+US$0.065 · +0.70%
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
前收盤價
US$9.32
+US$0.065 · +0.70%
盤中時間採用ET。市場資料可能有所延遲。
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
日內區間
目前US$9.32
52週區間
目前US$9.32
盤中時間採用ET。市場資料可能有所延遲。
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
日內區間
目前US$9.32
52週區間
目前US$9.32
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（GBP） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 110.3億 GBP | 112.33億 GBP | 113.02億 GBP | 108.58億 GBP | 95.45億 GBP |
| 銷貨成本 | 38.32億 GBP | 42.85億 GBP | 43.41億 GBP | 42.81億 GBP | 35.95億 GBP |
| 毛利 | 69.87億 GBP | 69.48億 GBP | 69.61億 GBP | 65.77億 GBP | 59.5億 GBP |
| 研究與開發 | 3.08億 GBP | 2.98億 GBP | 3.11億 GBP | 3億 GBP | 2.57億 GBP |
| 銷售、一般及管理費用 | 43.64億 GBP | 43.33億 GBP | 42.88億 GBP | 40.37億 GBP | 37.93億 GBP |
| 營業費用 | 44.29億 GBP | 47.42億 GBP | 49.65億 GBP | 47.52億 GBP | 43.12億 GBP |
| 利息收入 | 7629.07萬 GBP | 5500萬 GBP | 1400萬 GBP | 6897.97萬 GBP | 1300萬 GBP |
| 利息支出 | 3.33億 GBP | 3.94億 GBP | 4.14億 GBP | 3.47億 GBP | 1600萬 GBP |
| 折舊和攤銷 | 3.52億 GBP | 3.24億 GBP | 3.09億 GBP | 2.87億 GBP | 2.68億 GBP |
| 營業利益 | 24.12億 GBP | 22.06億 GBP | 19.96億 GBP | 18.25億 GBP | 16.38億 GBP |
| 淨利 | 16.3億 GBP | 14.42億 GBP | 10.49億 GBP | 10.6億 GBP | 13.9億 GBP |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅4項
報告持有此股票曝險的交易所交易基金。
State Street SPDR Portfolio Developed World ex-US ETFSPDW5070.65萬0.13%404.62億 USD0.03%US$49.98+0.64%
VanEck Pharmaceutical ETFPPH3899.74萬3.80%10.37億 USD0.36%US$110.49+1.20%
Principal Exchange-Traded Funds - Principal International Equity ETFPIEQ3294.53萬2.49%13億 USD0.48%US$35.59+0.57%
Avantis International Equity ETFAVDE853.55萬0.04%192.24億 USD0.23%US$89.80+0.58%
Portfolio Building Block World Pharma and Biotech Index ETFPBPH564.7萬0.55%10.27億 USD0.13%US$28.3551+1.40%
Scharf Global Opportunity ETFGKAT436.11萬2.65%1.65億 USD0.59%US$44.7957+0.66%
ETF Opportunities Trust - AQE Core ETFAQEC424.62萬0.70%6.05億 USD0.49%US$26.02+0.35%
Franklin ClearBridge Enhanced Income ETFYLDE395.07萬2.27%1.75億 USD0.48%US$55.525+0.31%State Street SPDR Portfolio Developed World ex-US ETFSPDWVanEck Pharmaceutical ETFPPHPrincipal Exchange-Traded Funds - Principal International Equity ETFPIEQAvantis International Equity ETFAVDEPortfolio Building Block World Pharma and Biotech Index ETFPBPHScharf Global Opportunity ETFGKATETF Opportunities Trust - AQE Core ETFAQECFranklin ClearBridge Enhanced Income ETFYLDEAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
